B-intervention	0	8	Complete
I-intervention	9	17	axillary
I-intervention	18	23	lymph
I-intervention	24	28	node
I-intervention	29	39	dissection
O	40	46	versus
B-control	47	55	clinical
I-control	56	62	follow
I-control	62	63	-
I-control	63	65	up
O	66	68	in
O	69	75	breast
O	76	82	cancer
O	83	91	patients
O	92	96	with
O	97	105	sentinel
O	106	110	node
O	111	126	micrometastasis
O	126	127	:
O	128	133	final
O	134	141	results
O	142	146	from
O	147	150	the
O	151	162	multicenter
O	163	171	clinical
O	172	177	trial
O	178	183	AATRM
O	184	187	048
O	187	188	/
O	188	190	13
O	190	191	/
O	191	195	2000
O	195	196	.

O	197	199	It
O	200	203	has
O	204	208	been
O	209	218	suggested
O	219	223	that
O	224	233	selective
O	234	242	sentinel
O	243	247	node
O	248	249	(
O	249	251	SN
O	251	252	)
O	253	259	biopsy
O	260	265	alone
O	266	269	can
O	270	272	be
O	273	277	used
O	278	280	to
O	281	287	manage
O	288	293	early
O	294	300	breast
O	301	307	cancer
O	307	308	,
O	309	312	but
O	313	321	definite
O	322	330	evidence
O	331	333	to
O	334	341	support
O	342	346	this
O	347	353	notion
O	354	356	is
O	357	364	lacking
O	364	365	.

O	366	369	The
O	370	373	aim
O	374	376	of
O	377	381	this
O	382	387	study
O	388	391	was
O	392	394	to
O	395	406	investigate
O	407	414	whether
O	415	425	refraining
O	426	430	from
O	431	441	completion
O	442	450	axillary
O	451	456	lymph
O	457	461	node
O	462	472	dissection
O	473	474	(
O	474	478	ALND
O	478	479	)
O	480	488	suffices
O	489	491	to
O	492	499	produce
O	500	503	the
O	504	508	same
O	509	519	prognostic
O	520	531	information
O	532	535	and
O	536	543	disease
O	544	551	control
O	552	554	as
O	555	565	proceeding
O	566	570	with
O	571	581	completion
O	582	586	ALND
O	587	589	in
O	590	595	early
O	596	602	breast
O	603	609	cancer
O	610	618	patients
O	619	626	showing
O	627	642	micrometastasis
O	643	645	at
O	646	648	SN
O	649	655	biopsy
O	655	656	.

O	657	661	This
O	662	673	prospective
O	673	674	,
O	675	685	randomized
O	686	694	clinical
O	695	700	trial
O	701	709	included
B-eligibility	710	718	patients
I-eligibility	719	723	with
I-eligibility	724	729	newly
I-eligibility	730	739	diagnosed
I-eligibility	740	745	early
I-eligibility	745	746	-
I-eligibility	746	751	stage
I-eligibility	752	758	breast
I-eligibility	759	765	cancer
I-eligibility	766	767	(
I-eligibility	767	768	T
I-eligibility	768	769	<
I-eligibility	769	770	3
I-eligibility	770	771	.
I-eligibility	771	772	5
I-eligibility	773	775	cm
I-eligibility	775	776	,
I-eligibility	777	785	clinical
I-eligibility	786	788	N0
I-eligibility	788	789	,
I-eligibility	790	792	M0
I-eligibility	792	793	)
I-eligibility	794	797	who
I-eligibility	798	807	underwent
I-eligibility	808	816	surgical
I-eligibility	817	825	excision
I-eligibility	826	828	as
I-eligibility	829	836	primary
I-eligibility	837	846	treatment
O	846	847	.

O	848	851	All
O	852	855	had
O	856	871	micrometastatic
O	872	874	SN
O	874	875	.

O	876	884	Patients
O	885	889	were
O	890	898	randomly
O	899	907	assigned
O	908	910	to
O	911	914	one
O	915	917	of
O	918	921	the
O	922	925	two
O	926	931	study
O	932	936	arms
O	936	937	:
O	938	946	complete
O	947	951	ALND
O	952	953	(
O	953	960	control
O	961	964	arm
O	964	965	)
O	966	968	or
O	969	977	clinical
O	978	984	follow
O	984	985	-
O	985	987	up
O	988	989	(
O	989	1001	experimental
O	1002	1005	arm
O	1005	1006	)
O	1006	1007	.

O	1008	1014	Median
O	1015	1021	follow
O	1021	1022	-
O	1022	1024	up
O	1025	1028	was
O	1029	1030	5
O	1031	1036	years
O	1036	1037	,
O	1038	1048	recurrence
O	1049	1052	was
O	1053	1061	assessed
O	1061	1062	,
O	1063	1066	and
O	1067	1070	the
O	1071	1078	primary
O	1079	1082	end
O	1083	1088	point
O	1089	1092	was
B-outcome-Measure	1093	1100	disease
I-outcome-Measure	1100	1101	-
I-outcome-Measure	1101	1105	free
I-outcome-Measure	1106	1114	survival
O	1114	1115	.

O	1116	1120	From
O	1121	1122	a
O	1123	1128	total
O	1129	1135	sample
O	1136	1138	of
B-total-participants	1139	1142	247
O	1143	1151	patients
O	1151	1152	,
O	1153	1155	14
O	1156	1164	withdrew
O	1164	1165	,
O	1166	1173	leaving
B-control-participants	1174	1177	112
O	1178	1180	in
O	1181	1184	the
O	1185	1192	control
O	1193	1196	arm
O	1197	1200	and
B-intervention-participants	1201	1204	121
O	1205	1207	in
O	1208	1211	the
O	1212	1224	experimental
O	1225	1228	arm
O	1228	1229	.

O	1230	1232	In
B-cv-bin-abs	1233	1235	15
O	1236	1243	control
O	1244	1252	subjects
O	1253	1254	(
B-cv-bin-percent	1254	1256	13
I-cv-bin-percent	1256	1257	%
O	1257	1258	)
O	1258	1259	,
B-outcome	1260	1270	completion
I-outcome	1271	1275	ALND
I-outcome	1276	1279	was
I-outcome	1280	1288	positive
O	1288	1289	,
O	1290	1294	with
O	1295	1296	a
O	1297	1300	low
O	1301	1306	tumor
O	1307	1313	burden
O	1313	1314	.

O	1315	1319	Four
O	1320	1328	patients
O	1329	1340	experienced
B-outcome	1341	1348	disease
I-outcome	1349	1359	recurrence
O	1359	1360	:
B-cv-bin-abs	1361	1362	1
O	1363	1364	(
B-cv-bin-percent	1364	1365	1
I-cv-bin-percent	1365	1366	%
O	1366	1367	)
O	1368	1370	of
B-control-participants	1371	1374	108
O	1375	1382	control
O	1383	1391	subjects
O	1392	1395	and
B-iv-bin-abs	1396	1397	3
O	1398	1399	(
B-iv-bin-percent	1399	1400	2
I-iv-bin-percent	1400	1401	.
I-iv-bin-percent	1401	1402	5
I-iv-bin-percent	1402	1403	%
O	1403	1404	)
O	1405	1407	of
B-intervention-participants	1408	1411	119
O	1412	1424	experimental
O	1425	1433	patients
O	1433	1434	.

O	1435	1440	There
O	1441	1445	were
O	1446	1448	no
O	1449	1460	differences
O	1461	1463	in
B-outcome	1464	1471	disease
I-outcome	1471	1472	-
I-outcome	1472	1476	free
I-outcome	1477	1485	survival
O	1486	1487	(
O	1487	1488	p
O	1488	1489	=
O	1489	1490	0
O	1490	1491	.
O	1491	1494	325
O	1494	1495	)
O	1496	1503	between
O	1504	1508	arms
O	1509	1512	and
O	1513	1515	no
B-outcome	1516	1522	cancer
I-outcome	1522	1523	-
I-outcome	1523	1530	related
I-outcome	1531	1537	deaths
O	1537	1538	.

O	1539	1542	Our
O	1543	1550	results
O	1551	1559	strongly
O	1560	1567	suggest
O	1568	1572	that
O	1573	1575	in
O	1576	1581	early
O	1582	1588	breast
O	1589	1595	cancer
O	1596	1604	patients
O	1605	1609	with
O	1610	1612	SN
O	1613	1628	micrometastasis
O	1628	1629	,
O	1630	1639	selective
O	1640	1642	SN
O	1643	1658	lymphadenectomy
O	1659	1667	suffices
O	1668	1670	to
O	1671	1678	control
O	1679	1691	locoregional
O	1692	1695	and
O	1696	1703	distant
O	1704	1711	disease
O	1711	1712	,
O	1713	1717	with
O	1718	1720	no
O	1721	1732	significant
O	1733	1740	effects
O	1741	1743	on
O	1744	1752	survival
O	1752	1753	.
